GLRB Antibody

What is GLRB and why is it important in neuroscience research?

GLRB (Glycine Receptor Beta) is a subunit of glycine receptors (GlyRs), which are ligand-gated chloride channels belonging to the nicotinic acetylcholine receptor superfamily. GlyRs mediate inhibitory neurotransmission in the spinal cord, brain stem, and some higher brain regions . The pentameric structure of GlyRs typically consists of α and β subunits arranged in a 4α:1β stoichiometry .

Beyond its structural role, GLRB also contributes significantly to GlyR function. Mutations in GLRB have been associated with startle disease (hyperekplexia), which shares phenotypic symptoms with stiff-person syndrome (SPS) . Recent research has established GLRB as the third major gene of effect in hyperekplexia, following GLRA1 and SLC6A5/GlyT2 .

What are the typical molecular characteristics of GLRB antibodies?

Most commercially available GLRB antibodies are:

• Molecular Weight: Detects proteins at approximately 56 kDa

• Common Host Species: Primarily rabbit, with some mouse options available

• Available Forms: Both polyclonal and monoclonal (e.g., clone 3B8A8)

• Storage Requirements: Most require storage at -20°C with glycerol and preservation agents

The immunogens used for antibody production typically target:

• Internal region peptides of human GlyRβ

• The N-terminal domain (amino acids 23-265)

• The second intracellular loop (e.g., residues 394-405 in rat GlyRβ)

What are the validated applications for GLRB antibodies?

Based on the search results, GLRB antibodies have been validated for multiple applications with different dilution recommendations:

How can I optimize Western blot conditions for detecting GLRB?

For optimal Western blot detection of GLRB:

• Sample Preparation: Use brain or spinal cord tissue lysates, which show high GLRB expression

• Gel Type: 11% (w/v) SDS-PAGE gels are suitable for separating the 56 kDa GLRB protein

• Transfer Method: Transfer proteins onto nitrocellulose membranes

• Blocking: Use 5% BSA or 5% milk powder in TBS-T (TBS with 1% v/v Tween20) for 1 hour

• Primary Antibody: Dilute 1:500-1:2000 in blocking buffer and incubate overnight at 4°C

• Secondary Antibody: Use HRP-conjugated anti-rabbit or anti-mouse IgG (typically 1:15000)

• Detection: Use chemiluminescence with clarity Western ECL substrate

• Validation Control: Consider using blocking peptides specific to GLRB antibodies to confirm specificity

As demonstrated in published research, mouse and rat brain lysates typically yield clear bands at the expected 56 kDa molecular weight .

What protocol should I follow for immunohistochemistry with GLRB antibodies?

For immunohistochemistry of GLRB in neural tissues:

For Frozen Sections:

• Obtain free-floating frozen brain sections from paraformaldehyde-perfused specimens

• Incubate with anti-GLRB antibody (1:300 dilution recommended)

• Follow with appropriate secondary antibody (e.g., goat anti-rabbit conjugated to Alexa Fluor 488)

• Include nuclear counterstain (e.g., DAPI)

For Paraffin Sections:

• Recommended dilution: 1:50-1:500

• Antigen retrieval: Use TE buffer pH 9.0 (alternatively, citrate buffer pH 6.0)

• Include appropriate negative controls

Specific anatomical regions showing strong GLRB immunoreactivity include:

• Mouse cerebellum: Purkinje layer and single interneurons in the granule layer

• Rat substantia nigra pars compacta (SNC)

How do autoantibodies against GlyRβ contribute to neurological disorders?

Recent research has identified GlyRβ as a novel target of autoantibodies (aAbs) in patients with stiff-person syndrome (SPS) and progressive encephalomyelitis with rigidity and myoclonus (PERM) .

Key findings include:

• Novel Discovery: Among 58 samples investigated, cell-based assays, tissue analysis, and preadsorption approaches revealed 2 patients with high specificity for GlyRβ aAb

• Binding Characteristics: Quantitative protein cluster analysis demonstrated aAb binding to synaptic GlyRβ colocalized with the scaffold protein gephyrin, independent of GlyRα1 presence

• Functional Consequences: Unlike GlyRα1-positive sera that alter glycine potency, aAbs against GlyRβ impair receptor efficacy for glycine

• Mechanism of Action: GlyRβ aAbs antagonize inhibitory neurotransmission by affecting receptor function rather than localization

This represents a significant advancement in understanding neurological disorders, as autoimmune reactivity against GlyRβ subunits had not been previously demonstrated, despite the high sequence homology between the extracellular N-terminal domains of GlyRα and GlyRβ .

What methods are used to investigate GLRB-specific autoantibodies?

The detection and characterization of GLRB-specific autoantibodies employ multiple complementary approaches:

• Cell-Based Assays:

  • GlyRβ is expressed with a myc tag and detected with antimyc antibody

  • Patient serum binding is verified with anti-human-IgG-Cy3 antibody

• Microarray Binding Assays:

  • Microarray slides are blocked with 5% milk powder, 0.05% Tween20, and PBS (pH 7.4)

  • Slides are incubated with patient sera (1:500) or control antibodies

  • IgG detection uses goat-anti-human or goat-anti-mouse-IgG-HRP

  • Binding intensities are quantified with FIJI using the "microarray profile" plugin

• Tissue Immunohistochemistry:

  • Spinal cord tissues are treated with 50 mM NH4Cl for quenching

  • Incubation in 0.1 mM glycine for 30 minutes

  • Blocking with 10% goat serum in PBS (pH 7.4)

  • Primary antibody incubation with patient serum (1:50) overnight at 4°C

  • Secondary antibody detection with goat-anti-human-IgG-Alexa-Fluor-647

• Functional Assessment:

  • Whole-cell patch-clamp recordings to resolve functional consequences of GlyRβ aAb binding

  • Assessment of glycine efficacy and potency changes

How have AI approaches advanced antibody design for targets like GLRB?

Recent developments in artificial intelligence are transforming antibody design, particularly for specific targets:

How can I distinguish between GlyRα and GlyRβ binding in experimental settings?

Distinguishing between GlyRα and GlyRβ binding requires specific methodological approaches:

• Antibody Selection:

  • Use subunit-specific antibodies: anti-myc-tagged GlyRβ (e.g., Synaptic Systems #303008, 1:250)

  • For GlyRα, use pan-α-GlyR antibodies (e.g., Synaptic Systems #146011, 1:250)

• Preadsorption Approaches:

  • Use living cells expressing specific subunits

  • Use purified extracellular receptor domains for preadsorption of antibodies

  • Pre-incubate antibodies with specific blocking peptides (e.g., Glycine Receptor β Blocking Peptide)

• Structural Visualization:

  • The cryo-EM structure (7MLY) of the pentameric GlyR with a 4α:1β stoichiometry can help identify subunit-specific binding regions

  • Use PyMol software (version 2.0.7 or newer) to analyze structural features and binding sites

• Co-localization Studies:

  • GlyRβ co-localizes with the scaffold protein gephyrin

  • Perform dual labeling with anti-gephyrin antibodies (e.g., Synaptic Systems #147111, 1:500)

What are the best protocols for validating GLRB antibody specificity?

Validating GLRB antibody specificity is critical for reliable experimental results. Multiple approaches should be employed:

• Western Blot Validation:

  • Compare antibody detection in positive samples (brain/spinal cord tissues) versus negative controls

  • Look for a single band at the expected molecular weight (56 kDa)

  • Perform pre-adsorption tests with blocking peptides specific to the immunogen used to raise the antibody

• Immunohistochemistry Controls:

  • Include parallel sections with primary antibody pre-incubated with blocking peptide

  • Example: Pre-incubation of anti-GLRB antibody with Glycine Receptor β Blocking Peptide (#BLP-GR014) should substantially reduce or eliminate staining

• Knockout/Knockdown Controls:

  • When available, use tissues/cells from GLRB knockout or knockdown models as negative controls

  • Compare staining patterns in wild-type versus KO/KD samples

• Cross-reactivity Assessment:

  • Test the antibody against closely related proteins (especially GlyRα subunits)

  • Verify species cross-reactivity using sequence alignment tools and experimental validation

• Multi-antibody Approach:

  • Compare results using multiple antibodies targeting different epitopes of GLRB

  • Consistent results across different antibodies increase confidence in specificity

What are the critical factors for studying GLRB in primary neuronal cultures?

When studying GLRB in primary neuronal cultures, several critical factors should be considered:

• Culture Preparation:

  • Primary spinal cord neurons are optimal for GLRB studies since glycine receptors are highly expressed in the spinal cord

  • Ensure proper neuronal differentiation and maturation (typically 14-21 days in vitro)

• Immunocytochemistry Protocol:

  • Fix cells with 4% paraformaldehyde

  • Block with 10% goat serum in PBS

  • Primary antibodies: Use anti-GLRB (1:250-1:300) along with markers for inhibitory synapses such as gephyrin (1:500) and synapsin (1:500)

  • Secondary antibodies: Use appropriately conjugated antibodies (1:500) that don't cross-react

  • Include nuclear staining with DAPI

• Functional Assessment:

  • Whole-cell patch-clamp recordings are essential for assessing GLRB functionality

  • Measure glycine-induced currents to evaluate receptor efficacy and potency

  • Compare wild-type response with manipulated conditions (e.g., antibody treatment)

• Quantitative Analysis:

  • For protein cluster analysis, co-localization of GLRB with synaptic markers should be quantified

  • Evaluate GLRB expression at synaptic versus extrasynaptic locations

  • Measure clustering with and without experimental manipulations

• Controls and Validations:

  • Include appropriate controls (untreated, isotype controls, blocking peptide controls)

  • Validate antibody specificity in your specific culture system

What are common issues when using GLRB antibodies and how can they be resolved?

Based on the search results and general antibody troubleshooting principles:

How do GLRB expression patterns vary across different brain regions and how might this affect antibody selection?

GLRB expression shows regional variation within the nervous system, which has important implications for antibody selection and experimental design:

• Regional Expression Patterns:

  • High expression: Spinal cord, brainstem, cerebellum (particularly in Purkinje cells)

  • Moderate expression: Substantia nigra pars compacta

  • Lower/specialized expression: Higher brain regions

• Cell-Type Specificity:

  • In cerebellum: Strong expression in Purkinje layer and interneurons in the granule layer

  • In spinal cord: Strong expression in inhibitory synapses

• Implications for Antibody Selection:

  • For high-expressing regions like spinal cord: Standard sensitivity antibodies are sufficient

  • For regions with lower expression: High-sensitivity detection methods may be required

  • For specific neuronal populations: Consider co-labeling with cell-type specific markers

• Experimental Considerations:

  • Always include positive control tissues (e.g., spinal cord) when testing new antibodies

  • Expect variation in optimal antibody concentration depending on the brain region studied

  • For weaker signals, signal amplification methods may be necessary

• Visualization Strategies:

  • For weaker expressing regions: Consider tyramide signal amplification

  • For co-localization studies: Select antibodies raised in different host species to allow simultaneous detection

Understanding these expression patterns helps researchers select appropriate positive controls and optimize protocols for specific brain regions, enhancing the reliability of GLRB detection across different neural tissues.